Keyphrases
Japan
100%
Vaccination Program
100%
13-valent Pneumococcal Conjugate Vaccine (PCV13)
100%
Japanese Yen
100%
Cost-effectiveness Analysis
100%
20-valent Pneumococcal Conjugate Vaccine
100%
Pediatric Vaccination
100%
United States
80%
PCV20
80%
Quality-adjusted Life Years
60%
Payer Perspective
60%
Societal Perspective
40%
Pediatric Vaccines
40%
Pneumonia
20%
Cost-effectiveness
20%
Pediatric
20%
Invasive Pneumococcal Disease
20%
Otitis Media
20%
Incremental Cost-effectiveness Ratio
20%
Expected Cost
20%
Markov Model
20%
National Immunization Program
20%
Healthcare Payer
20%
Pneumococcal Infections
20%
Acquisition Cost
20%
Decision-analytic Model
20%
Threshold Analysis
20%
Medicine and Dentistry
Pediatrics
100%
Cost-Effectiveness Analysis
100%
Pneumococcus Vaccine
100%
Quality Adjusted Life Year
75%
Health Care Cost
50%
Pneumococcal Infection
50%
Base
25%
Acute Otitis Media
25%